lung cancer

[Cancer Research] Researchers identified that loss of an epigenetic factor, lysine methyltransferase 5C (KMT5C), drove resistance of NSCLC to multiple EGFR inhibitors, including erlotinib, gefitinib, afatinib, and osimertinib.

[Nature Genetics] Scientists applied single-cell whole-genome sequencing of proximal bronchial basal cells from 33 participants aged between 11 and 86 years with smoking histories varying from never-smoking to 116 pack-years.

[Cell Death Discovery] The authors found that SH3PXD2A-AS1 expression in NSCLC tissues was upregulated compared with that in normal lung tissues in The Cancer Genome Atlas database by using the GEPIA website.

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

[Janssen Pharmaceutical Companies] The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada has issued a Notice of Compliance with Conditions approving RYBREVANT®, a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic NSCLC.